Processa Pharmaceuticals, Inc. (PCSA)

US — Healthcare Sector
Peers: ACOGF  EPRXF  ACXP  FENC  CMRA  SABS  FRTX  THRD  ELYM  INBX  MACK  CELC  ELVN  ANTX  MIRO  IKT  PMVP  ANEB  AKTX  ARMP  SCPS 

Automate Your Wheel Strategy on PCSA

With Tiblio's Option Bot, you can configure your own wheel strategy including PCSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PCSA
  • Rev/Share 0.0
  • Book/Share 0.3702
  • PB 0.7902
  • Debt/Equity 0.0141
  • CurrentRatio 2.9291
  • ROIC -2.6267

 

  • MktCap 3476187.0
  • FreeCF/Share -0.9656
  • PFCF -0.3779
  • PE -0.233
  • Debt/Assets 0.0103
  • DivYield 0
  • ROE -3.1958

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Processa Pharmaceuticals, Inc. (PCSA)

  • IPO Date 2014-03-07
  • Website https://www.processapharmaceuticals.com
  • Industry Biotechnology
  • CEO Mr. George K. Ng Esq., J.D.
  • Employees 10
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.